D. E. Shaw & Co. Inc. Sells 371,704 Shares of Qiagen (NYSE:QGEN)

D. E. Shaw & Co. Inc. cut its holdings in Qiagen (NYSE:QGEN - Free Report) by 60.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 248,131 shares of the company's stock after selling 371,704 shares during the quarter. D. E. Shaw & Co. Inc. owned approximately 0.11% of Qiagen worth $11,049,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Brown Brothers Harriman & Co. bought a new stake in Qiagen in the fourth quarter worth $37,000. Geneos Wealth Management Inc. raised its position in shares of Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after purchasing an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after purchasing an additional 526 shares in the last quarter. Smartleaf Asset Management LLC grew its position in Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after purchasing an additional 835 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its position in Qiagen by 83.5% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company's stock valued at $70,000 after purchasing an additional 712 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $41.23 on Thursday. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $9.17 billion, a PE ratio of 114.81, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. The firm's 50 day moving average price is $40.83 and its 200-day moving average price is $41.78. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.50 by $0.05. The business had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The company's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $0.44 earnings per share. Equities research analysts expect that Qiagen will post 2.26 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on QGEN shares. Robert W. Baird upped their price objective on Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. StockNews.com upgraded Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 19th. Finally, UBS Group dropped their price target on shares of Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Seven equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $48.42.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.